TELA Bio (TELA) Liabilities and Shareholders Equity (2018 - 2025)
TELA Bio has reported Liabilities and Shareholders Equity over the past 8 years, most recently at $81.4 million for Q4 2025.
- Quarterly results put Liabilities and Shareholders Equity at $81.4 million for Q4 2025, down 5.95% from a year ago — trailing twelve months through Dec 2025 was $287.8 million (up 5.95% YoY), and the annual figure for FY2025 was $81.4 million, down 5.95%.
- Liabilities and Shareholders Equity for Q4 2025 was $81.4 million at TELA Bio, up from $61.6 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for TELA hit a ceiling of $94.4 million in Q2 2023 and a floor of $51.3 million in Q2 2022.
- Median Liabilities and Shareholders Equity over the past 5 years was $70.3 million (2021), compared with a mean of $70.8 million.
- Biggest five-year swings in Liabilities and Shareholders Equity: surged 83.87% in 2023 and later tumbled 39.28% in 2024.
- TELA Bio's Liabilities and Shareholders Equity stood at $62.5 million in 2021, then increased by 8.49% to $67.9 million in 2022, then rose by 15.02% to $78.0 million in 2023, then increased by 10.92% to $86.6 million in 2024, then fell by 5.95% to $81.4 million in 2025.
- The last three reported values for Liabilities and Shareholders Equity were $81.4 million (Q4 2025), $61.6 million (Q3 2025), and $67.5 million (Q2 2025) per Business Quant data.